Aileron Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview

Rein Therapeutics

18/03/2024 12:59

* Aileron Therapeutics Inc  ALRN.OQ   ALRN.O  is expected
to report results on March 20 (estimated) for the period ending
December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Aileron Therapeutics Inc
is
for a loss of 16 cents per share. 
    * The one available analyst rating on the shares is
"hold".  
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "Hold".​
    * Wall Street's median 12-month price target for Aileron
Therapeutics Inc is $9.00​, above​ its last closing price
of $5.58. ​​​

This summary was machine generated March 18 at 12:59 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)